Low molecular-weight heparins (clexan, fraxiparin, fragmin) were used in cancer patients to prevent hemostatic system disorders and related complications. The adequacy and safety of therapy were assessed measuring plasma anti-Xa activity in 239 patients. When the prophylactic doses of the low molecular-weight heparins clexan, fraxiparin, and fragmin were given, their anticoagulative effect was similar as judged from anti-Xa activity. Clexan exhibited the maximum anti-Xa activity when the therapeutic doses of the low molecular-weight heparins were used.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
anti-xa activity
16
low molecular-weight
12
molecular-weight heparins
12
heparins clexan
8
clexan fraxiparin
8
fraxiparin fragmin
8
doses low
8
[determination anti-xa
4
activity
4
activity cancer
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!